Services

EnquBio's Comprehensive Drug Discovery Solutions & Services

At EnquBio, our expert team delivers high quality, efficient, and dependable R&D solutions that enable pharmaceutical and biotech partners to advance and expand their drug development pipelines.

Inflammation & Autoimmunity

From immune mechanism to disease-relevant response—one integrated platform for inflammation and autoimmune programs.

EnquBio supports inflammation and autoimmune drug programs with functional immunology assays, ex vivo pharmacology in human and preclinical samples, established in vivo disease models, and quantitative biomarker readouts—designed and run by one team, so mechanism, efficacy, and biomarkers stay connected across the program.

Inflammation and Autoimmunity

Functional Immunology Assays

Precise evaluation of compound effects on immune-cell function in controlled, human-relevant systems—with access to banked and fresh human PBMCs, T cells, B cells, NK cells, and myeloid populations.

T-Cell Biology

  • T-cell activation
  • T helper cell differentiation
  • Proliferation and cytokine secretion
  • Activation-marker expression

B-Cell Biology

  • B-cell stimulation
  • Activation and differentiation
  • Functional readouts

Innate Immunity

  • Macrophage polarization
  • Dendritic-cell polarization
  • Myeloid-cell function

Customized Readouts

  • Cytokine secretion
  • Surface-marker profiling
  • Cytotoxicity
  • Assays tailored to each program

Disease-Relevant Pharmacology

Move from clean-system mechanism to disease-relevant response using primary samples and established models.

Ex Vivo

Whole Blood & PBMC Pharmacology

Stimulation and challenge assays with phospho-signaling (pSTAT), cytokine release, and immune profiling—across human donors and preclinical species including cynomolgus monkey, dog, rat, and mouse.

In Vivo

Inflammation & Autoimmune Models

Established in vivo disease models with integrated PK/PD, biomarker, and downstream ex vivo functional analysis from the same studies.

Biomarkers

Cytokine & Signaling Readouts

Multiplex MSD cytokine and chemokine analysis, Jess protein and phosphoprotein analysis, flow cytometry immunophenotyping, and gene-expression readouts.

Respiratory · Featured Model

Human Airway ALI Model

A differentiated NHBE air–liquid interface epithelium with a validated Type 2 (IL-4 / IL-13) response for asthma, COPD, and respiratory programs.

Primary human bronchial epithelial cells differentiate at the air–liquid interface into a pseudostratified mucociliary epithelium with MUC5AC+ goblet cells and ciliated cells, stable for up to 2 months. IL-4 / IL-13 stimulation reproduces the goblet-cell, mucin, and chemokine signature of Type 2 asthma, giving a disease-relevant human system for compound evaluation.

  • Primary NHBE cells
  • Day 28 mature epithelium
  • IL-4 / IL-13 validated
  • RT-qPCR · ELISA · IHC

One Program, Connected Readouts

MechanismFunctional immunology assays
Human RelevanceWhole blood / PBMC ex vivo pharmacology
EfficacyIn vivo disease models
PK/PD & BiomarkersExposure, signaling, cytokines
TranslationCross-species comparison to human biology

Planning an inflammation or autoimmune program?

Share your target, pathway, and stage. Our scientists can propose the assay systems, models, and biomarker strategy that best connect mechanism with disease-relevant response.

Contact Our Scientists →
Functional immunology in primary human cells
Ex vivo pharmacology across five species
In vivo models with integrated biomarkers